The Partnering Agreements with Salix Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

The Partnering Agreements with Salix Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.   This report provides all the information you require to better understand Salix Pharmaceuticals and its partnering interests and activities over the past five years.   On demand company reports are prepared upon purchase more »

Salix Pharmaceuticals is a leading specialty pharmaceutical company, listed in the top 50 big biotech list by Current Partnering.

Specialty Pharmaceuticals Company Salix Pharmaceuticals is committed to providing treatments for a wide spectrum of gastrointestinal disorders.

Salix Pharmaceuticals has announced 3 M&A deals since 2009, with the deals being the acquisition of Santarus, Oceana Therapeutics and the merger between Salix and Cosmo Pharmaceuticals.

M&A news: The Canadian pharma company Valeant Pharmaceuticals is rumoured to be raising money to make a bid for specialty drugmaker Salix Pharmaceuticals, according to Bloomberg, which cites people familiar with the matter.

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs.  

TPG Capital LP has been exploring a sale of Aptalis Pharma, a specialty drugmaker it has owned since 2008 and values at more than $3 billion, according to dealtalk.

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire

Deal making on the up in the past week, with major deals announced by GSK, Alcon, Shire and Asahi Kasei

Analysis of date from the leading deals and alliances service Current Agreements, shows that many deals have eye watering headline values, however these deals often require an enormous amount to be successful during the development phases in order for the full value of the deal to be realized

Endo International has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common stock of Salix Pharmaceuticals

Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix

Salix Pharmaceuticals and Cosmo Pharmaceuticals announced a definitive m&a agreement under which Salix will combine with Cosmo Technologies for $2.7 billion.

Salix Pharmaceuticals acquires specialty pharma, Santarus for a whopping $2.6 billion cash transaction. 

Forest Laboratories needs M&A deal to counter a projected 80 percent drop in profit this year as patents on its top-selling drugs start to expire